Biotech Omeros Corporation (OMER 2.94%) has been on a tear since the start of September. With momentum building from a product headed for a Food and Drug Administration review and analyst upgrades, shares are up almost 16% today and have more than doubled in the last month.
In the following video, from The Motley Fool's health-care show Market Checkup, analyst Max Macaluso discusses the market's enthusiasm about Omeros and the opportunities and risks investors should watch for.
Note: This video was recorded on Oct. 2, 2013.
